INTRODUCTION
®, Cancer, prostate cancer, Prostate
CANCER, PROSTATE CANCER, PROSTATE
Active Surveillance (AS) has increased dramatically over the last decade as a safe alternative to immediate treatment for patients with favorable risk prostate cancer (PCa). This strategy, however, has not been equally adopted across all racial/ethnic arms, with lower rates seen particularly in Black men.Genomic tests like Decipher Prostate Biopsy Genomic Classifier and the Oncotype DX Genomic Prostate Score® (GPS) are designed to provide orthogonal data beyond standard risk stratification schemas, such as those promulgated by the National Comprehensive Cancer Network (NCCN). Genomic testing refines risk classification, which has been shown to increase uptake in AS.This study, which utilizes data from a randomized controlled trial in a predominantly Black population,